Q-omics provides the consensus-scored ASB10 profile across patient tissues and cancer cell-line models. ASB10 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ASB10 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ASB10 RNA expression shows 6,645 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, KIRC, and STAD as cancer lineages where ASB10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASB10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASB10 survival associations across molecular data types. ASB10 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASB10 RNA expression–survival associations across cancer types. High ASB10 expression shows unfavorable associations in COAD, READ, KICH, HNSC, CHOL and THYM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ASB10 RNA expression.
This table summarizes ASB10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ASB10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASB10 shows lower tumor expression in KIRC, KIRP, HNSC and KICH and higher tumor expression in LUAD and LUSC. The KIRC box plot shows higher ASB10 RNA expression in normal versus tumor tissue (log2 FC = −0.081, t-test p < 0.001).
This table shows molecular features associated with ASB10 in patient tissues and cancer cell lines. In patient samples, ASB10 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ASB10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
